IRADIMED Q2 FY26 earnings call IRMD

IRadimed successfully executed the first general release production of its new 3870 MR IV pump system in Q2 FY26, achieving its manufacturing target of 130 to 135 units. The company plans to more than double production to over 300 units in Q3 FY26. This rapid ramp-up consumed significant effort and increased labor and overhead expenses, impacting Q2 gross margin, but management expects these start-up costs to be better than 50% reduced in Q3, with a return to historic efficiencies by Q4.

Bookings for the new 3870 pump system in Q2 FY26 were more than double the units shipped, leading to a building backlog. The demand is exceeding expectations in both unit volume and average selling price (ASP). A significant driver is the replacement opportunity for approximately 6,400 older 3860/61 pump channels in the U.S. market. Notably, 70% of these replacement orders were for the 4-channel quad pump system, which carries an ASP north of $110,000, representing over a 20% lift per pump.

Despite the focus on the 3870 pump launch, the sales team achieved a record high of 71 MRI-compatible patient vital signs monitors sold in the domestic market during Q2 FY26, maintaining a high ASP. Revenue from monitoring systems contributed $6.7 million, up 12% year-over-year. Ferro-magnetic Detection System revenue also grew significantly, up 57% to $0.8 million.

The company saw strong growth across its recurring revenue streams. Disposables revenue increased 14% to $4.8 million, driven by continued increases in device utilization. Amortization of extended maintenance agreements grew 28% to $0.8 million, and services and other revenue increased 7% to $1.1 million. The transition to 4-channel quad systems for the 3870 is expected to further drive utilization and future disposable revenue growth.

Gross profit margin for Q2 FY26 was 74%, down from 78% in Q2 FY25, primarily due to higher manufacturing costs associated with the initial production ramp of the 3870. Management anticipates gross margin to improve in the second half of the year as 3870 volumes build and manufacturing efficiencies take hold, with expectations of setting new records by Q4 FY26. Operating expenses decreased 4% year-over-year to $8.8 million, or 43% of revenue, reflecting lower G&A and R&D expenses, partially offset by higher sales commissions.

IRadimed ended Q2 FY26 with a strong cash and cash equivalents balance of $59.1 million, up from $51.2 million at year-end. Cash flow from operations for the first six months of FY26 was $14.2 million, an 18% increase over the prior year period. Non-GAAP free cash flow for the quarter was $5.5 million. The Board of Directors declared a quarterly cash dividend of $0.20 per share, payable on August 28, 2026.